Article
Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.
Clinical pharmacology and therapeutics - 1 Nov 2007
Jin Y, Wang Y-H, Miao J, Li L, Kovacs R J, Marunde R, Hamman M A, Philips S, Phillips S, Hilligoss J, Hall S D
Abstract excerpt
We hypothesized that CYP3A5 genotype contributes to the interindividual variability in verapamil response. Healthy subjects (n=26) with predetermined CYP3A5 genotypes were categorized as expressers (at least one CYP3A5(*)1 allele) and nonexpressers (subjects without a CYP3A5(*)1 allele). Verapamil pharmacokinetics and pharmacodynamics were determined after 7 days of dosing with 240 mg daily. There was a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.